Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medicaid Reimbursement Vns topic
No spam. Unsubscribe anytime.
Senate approves measure directing Medicaid to seek higher reimbursement for vagus nerve stimulation devices
Summary
The Senate passed AB 2 84, directing Nevada’s Department of Health and Human Services to seek federal authority to set reimbursement rates at or above 82% of cost for certain vagus nerve stimulation devices by Oct. 1, 2025.
The Nevada Senate passed Assembly Bill 2 84 unanimously, ordering Medicaid to pursue federal authority to provide reimbursement rates equal to or greater than 82% of cost for certain medical devices used to treat epilepsy.
Senator Dondero Loop described the amended bill on the floor: "Assembly bill 2 84, as amended, requires Medicaid to request on or before 10/01/2025, federal authority to provide reimbursement rates greater than or equal to 82% of the cost for a vagus nerve stimulation device."
The clerk recorded 20 yeses and zero noes; the bill "has received the constitutional majority as declared passed in order to the assembly." The transcript indicates the change requires the Department of Health and Human Services to seek federal approval (presumably a waiver or state plan amendment) but does not record whether federal approval has been requested previously, the devices' cost basis, or implementation details for providers and beneficiaries.
Floor remarks also show the Senate adopted an amendment (amendment 9 84) earlier that eliminated a specific subsection related to reimbursement requirements; the senator moving the amendment said amendment 9 84 "eliminates section 2 1 c to reimbursement requirements." The final bill on the floor retains the 82% target and the Oct. 1, 2025 deadline for seeking federal authority.
